Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

blogs

- PMLiVE

Dupixent bounce-back helps stem diabetes declines at Sanofi

CEO Brandicourt says Sanofi will “enter a new growth phase”

- PMLiVE

Ashfield and Sanofi scoop ICE award

Company wins the Most Effective Agency Collaboration Award for the second year running

- PMLiVE

Healthcare Comms news

Owen Health reveals UK pharma's social media ranking, Emotive presents scientific engagement award and Random42 wins a Golden Eagle award

- PMLiVE

The Pharma UK Twitter Ranking 2018 [RESEARCH]

The second edition in our Pharma Social Media Series, the UK Twitter Ranking.

An agency called Owen

UK Twitter Hero

The Pharma UK Twitter Ranking 2018 [RESEARCH]

The second edition in our Pharma Social Media Series, the UK Twitter Ranking.

An agency called Owen

Trending: using social media to understand your pharma market

Blue Latitude Health Senior Associate Consultant Jiayi Chen explains how you can use social media to get under the skin of customers and your competition.

Blue Latitude Health

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte

Alexander Davies considers the remarkable story of how one company broke with pharma convention to speak out on social media

Sanofi reception

Sanofi poaches Peugeot’s finance head

Jean-Baptiste Chasseloup de Chatillon joins the French drugmaker as chief financial officer

- PMLiVE

Evotec says Sanofi deal makes it anti-infectives powerhouse

Aims to inject biotech nimbleness into anti-infectives portfolio

Stepping up in social media: trust and participation are the new imperatives

For marketers the greatest fascination with digital and social engagement is their ability to be tracked and ‘measured’. But let’s be clear on what digital and social can actually deliver....

- PMLiVE

FDA starts review of Sanofi’s oral type 1 diabetes drug

The US regulator has started its review of Sanofi and Lexicon Pharma’s sotagliflozin for type 1 diabetes, which the firms say could have blockbuster potential.Sotagliflozin – which has the proposed...

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links